Evolving Therapeutic Strategies in the Multidisciplinary Management of Patients with Hepatocellular Carcinoma – Improving Outcomes
The management of Hepatocellular Carcinoma (HCC) should be conducted in a multidisciplinary setting to offer individualized therapy. Most patients with HCC are not candidates for curative treatments because of tumor extent or underlying liver dysfunction. Therefore, other options including liver directed therapy (TACE, TARE and SBRT) are considered for locoregional tumor control. Whereas systemic therapy is considered standard of care for patients with HCC with metastatic disease and/or macrovascular invasion (MVI). In the last decade, there have been several advances in treating advanced liver cancer, including advances in imaging and radiation treatment delivery [SABR using Photons, Protons, MRI guidance radiotherapy, TARE], as well as revolutionary advances in systemic therapy (Immunotherapy). Therefore, novel approaches exploring rational combinations of different LDTs in addition to LDTs and systemic therapies are of great interest. This activity discusses recent advances and evidence-based data in the multidisciplinary management of patients who are not candidates for curative surgical therapies.
Over the last few years, there have been many advances in the treatment of HCC. The goal of this activity is to discuss the available treatment options through case-based discussion. We have a panel of experts from different fields (Medical Oncology, Interventional Radiology, Radiation Oncology) and through different case presentations, we discuss the role of each one of these fields in the treatment of different cases.
Topic:
- Speaker Introductions and Case #1
Dayssy Alexandra Diaz Pardo, MD, MS
Higinia Rosa Cardenes, MD, PhD - Ablation and Catheter Based Locoregional Therapies
Nadine Abi-Jaoudeh, MD - Case #1 Continued
Higinia Rosa Cardenes, MD, PhD - MRI-Guided Radiation Therapy to Improve Outcomes in HCC
Hyun Kim, MD - Case #2 Presentation
Dayssy Alexandra Diaz Pardo, MD, MS - Optimizing Outcomes in Patients with Advanced Hepatocellular Carcinoma: The Evolving Role of Systemic Therapy
Tanios Bekaii-Saab, MD - Case #2 Continued
Dayssy Alexandra Diaz Pardo, MD, MS - Proton Therapy in the Treatment of HCC
Smith "Jim" Apisarnthanarax, MD - Q and A
Full Panel
This activity is available from August 20, 2024, through 11:59 p.m. Eastern time on August 19, 2026.
This activity was originally recorded at the 2023 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, diagnostic radiologists, interventional radiologists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the role of Stereotactic Radiotherapy (SABR/SBRT) in the treatment of patients diagnosed with HCC.
- Recognize the role of Catheter-based Locoregional Therapy in the treatment of HCC including Transarterial Radioembolization (TARE).
- Identify new Systemic Therapy options (Targeted Therapy and Immunotherapy) available for the treatment of HCC and how to better integrate them with local ablative techniques.
- Higinia Rosa Cardenes, MD, PhD, is employed by Weill Cornell Medicine.
- Dayssy Alexandra Diaz Pardo, MD, MS, is employed by The Ohio State University Comprehensive Cancer Center. Dr. Diaz serves as Vice-Chair of DEI for The Ohio State University.
- Hyun Kim, MD, is employed by Washington University School of Medicine. Dr. Kim receives grant/research funding and honoraria from Varian and ViewRay. Dr. Kim receives compensation for consulting with Novartis. Dr. Kim is the Founder and CEO of GlobalART and is Associate Editor of IJROBP.
- Smith Apisarnthanarax, MD, is employed by the University of Washington/Fred Hutchinson Cancer Center.
- Nadine Abi-Jaoudeh, MD, FSIR, CCRP, is employed by University of California-Irvine. Dr. Abi-Jaoudeh receives grant/research funding and salary support from UCI, Philips Medical Systems, Teclison, Guerbet SA, Varian, Instylla HES Inc., and Sirtex Medical Ltd. Dr. Abi-Jaoudeh receives compensation/payment as a consultant for Angiodynamics Inc., Genentech F. Hoffman - La Roche Ltd., AstraZeneca, Lynx Group LLC, Innova Vascular Inc., Pfizer, Boston Scientific Inc., Johnson & Johnson, Histosonics Inc. and Medtronic.
- Tanios Bekaii-Saab, MD, is employed by the Mayo Clinic Arizona. Dr. Bekaii-Saab receives grant/research funding from AstraZeneca, Genentech, Merck, BMS, Lilly, and Bayer. Dr. Bekaii-Saab receives compensation for consulting from Stemline, Abbvie, Blueprint Medicines, Boehringer Ingelheim, Janssen, Daiichi Sankyo, Natera, TreosBio, Celularity, Caladrius Biosciences, Exact Science, Sobi, Beigene, Kanaph, AstraZeneca, Deciphera, Zai Labs, Exelixis, MJH Life Sciences, Aptitude Health, Illumina, Foundation Medicine, Sanofi and Glaxo SmithKline. Dr. Bekaii-Saab receives royalties from Uptodate and holds patents with Imugene and Recursion. Dr. Bekaii-Saab serves on the scientific advisory board of Imugene, Immuneering, Xilis, Replimune, Artiva and Sun Biopharma.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
Nonmember: $149
Member: $99
Member-in-training: $49
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until August 19, 2026, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.